Gilead Sciences | GILD - Fremdkapital

Aktienkurs
145.53
Täglich Wechseln
0.32 0.22%
Monatlich
-6.27%
Jährlich
30.59%
Q1 Prognose
139.58




Fremdkapital Veränderung Datum
AbbVie USD 62.97B 12M 2025-09
Agios Pharmaceuticals USD 1.06M 0 2022-09
ALKERMES USD 285.82M 639K 2024-09
Alnylam Pharmaceuticals USD 2.48B 1.44B 2025-12
Amgen USD 50B 2.43B 2025-12
Biogen USD 6.29B 1.4M 2025-09
BioMarin Pharmaceutical USD 597.18M 513K 2025-12
Bristol-Myers Squibb USD 42.85B 1.62B 2025-12
Coherus Biosciences USD 294.85M 2.33M 2025-03
Eli Lilly USD 40.87B 5.6M 2025-12
Gilead Sciences USD 22.14B 5M 2025-09
GlaxoSmithKline GBP 14.71B 186M 2025-12
Glaxosmithkline GBP 20.02B 4.72B 2025-09
Incyte USD 30.2M 5.17M 2025-12
J&J USD 39.44B 30M 2025-12
Merck USD 39.97B 6B 2025-09
Moderna USD 610M 584M 2025-12
Neurocrine Biosciences USD 169.5M 500K 2023-03
Novartis USD 24.24B 174M 2025-09
Pfizer USD 57.41B 93M 2025-09
PTC Therapeutics USD 2.03B 193.22M 2025-12
Puma Biotechnology USD 10.87M 222K 2025-06
Regeneron Pharmaceuticals USD 2.71B 720.4M 2025-12
Sangamo BioSciences USD 0 0 2022-06
Sanofi EUR 15.72B 2.45B 2025-12
Sarepta Therapeutics USD 828.97M 206.17M 2025-12
United Therapeutics USD 100M 100M 2024-06
Vertex Pharmaceuticals USD 111.4M 1.4M 2025-03